Disease Control on Lanreotide Autogel ® 120 mg in a Patient with Metastatic Gastrinoma: A Case Report
We report a disease control on a long-acting SSA lanreotide in a patient with metastatic gastrinoma. A 60-year-old man, who had previously undergone a surgical resection of metastatic pancreatic gastrinoma, presented with abdominal bloating, edema in the lower limbs, fatigue, and weight loss. The gastrinoma relapse with additional metastases in the pancreas, duodenum, and liver was confirmed by positron emission tomography-computed tomography (PET-CT) scan; the patient ’s blood gastrin level was #x3e;5,000 ng/L. Treatment with the SSA octreotide long-acting release was initiated to treat the gastrinoma relapse. On the CT scan done in September 2011, the liver metastases were still identifiable. In December 2011, the treatment was switched to lanreotide Autogel® (120 mg every 2 weeks). Following the treatment, the gastrin levels were reduced to #x3c;1,200 ng/L in September 2013, and 812 ng/L in July 2016. Since November 2012, the gastrinoma lesions were no longer visible in abdominal CT. At the time of this report, the patient’s gastrinoma was under cont rol with lanreotide Autogel®. This case report supports the use of lanreotide Autogel® as effective treatment for metastatic gastrinoma.Case Rep Gastroenterol 2017;11:616 –623
CONCLUSIONS: In a prospective study of motion-corrected CBCT in GEJ and pancreas, RMC-CBCT yielded improved organ visibility and localization accuracy for gated treatment at end expiration in the majority of cases. PMID: 29350579 [PubMed - as supplied by publisher]
ConclusionMRI‐guided percutaneous biopsy of pancreatic lesions using an open 1.0T high‐field scanner has high diagnostic accuracy, which is feasible and safe for use in clinical practice.Level of Evidence: 2Technical Efficacy: Stage 2J. Magn. Reson. Imaging 2018.
Conclusion.R0 resection, the goal of neoadjuvant treatment, can be achieved in 70% of patients presenting with locally advanced pancreatic cancer. The median DFS was 31 months (95% CI: 11. 3–51.1). No relationship was found with tumor size, degree of vascular involvement, carcinoembryonic antigen test (CEA), CA 19‐9, degree of tumor regression on scan, fall in CA 19‐9, or SUV on PET scan and subsequent survival.
CONCLUSIONS: Prospective genomic profiling of advanced PDAC is feasible and our early data indicate that chemotherapy response differs among patients with different genomic/transcriptomic subtypes. PMID: 29288237 [PubMed - as supplied by publisher]
ConclusionsTo the best of our knowledge, this is the first report on biodistribution and radiation dosimetry of [64Cu]CuCl2 in healthy volunteers. Measured absorbed doses and effective doses are higher than previously reported doses estimated with biodistribution data from patients with prostate cancer, a difference that could be explained not just due to altered biodistribution in cancer patients compared to healthy volunteers but most likely due to the differences in the analysis technique and assumptions in the dose calculation.
CONCLUSION: R0 resection, the goal of neoadjuvant treatment, can be achieved in 70% of patients presenting with locally advanced pancreatic cancer. The median DFS was 31 months (95% CI: 11. 3-51.1). No relationship was found with tumor size, degree of vascular involvement, carcinoembryonic antigen test (CEA), CA 19-9, degree of tumor regression on scan, fall in CA 19-9, or SUV on PET scan and subsequent survival. PMID: 29212734 [PubMed - as supplied by publisher]
Conclusions: The ovary is a common site of metastases from GI, breast, liver, pancreas, kidney cancers, but very rarely from a primary lung (0.3-4%). Immunotherapy could be an useful therapeutic option for treatment expecially in young patients.
This report suggests that the appropriate treatment for this association in metastatic or unresectable disease is chemotherapy for pancreatic cancer and tyrosine kinase inhibitor for kidney cancer. We also review the appropriate literature concerning that association.Case Rep Oncol 2017;10:1050 –1056
We report a case in which combination therapy with albumin-bound paclitaxel (nab-paclitaxel) and gemcitabine converted unresectable pancreatic cancer with peritoneal metastases into resectable disease. The patient was a 71-year-old woman with anorexia. Enhanced abdominal computed tomography (CT) showed an atrophic pancreatic body and tail, dilated main pancreatic duct, peritoneal dissemination, portal vein stricture, bile duct stricture and wall thickening, and blockage of the right ureter. She was diagnosed with pancreatic cancer with peritoneal metastases. Curative resection was initially impossible. Combination therapy ...
AbstractBackgroundWe aimed to determine whether treatment should be stratified according to 18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) maximum standardized uptake values (SUVmax) in pancreatic ductal adenocarcinoma.MethodsPatients who underwent preoperative 18F-FDG PET/CT between 2006 and 2014 (n = 138) were stratified into high (≥ 4.85) and low (